Equity Analysis /
United States of America

US : Jounce Therapeutics, Inc. - JNCE | 3Q21 Update: Outlicensed CCR8 Antibody Goes Clinical

    Contributors
    Timur Ivannikov
    Ryan Deschner
    CGS-CIMB
    4 November 2021
    Published by